Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin
SOURCE CITATION: Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609-17. 34297496.
| Errataetall: |
CommentOn: N Engl J Med. 2021 Aug 12;385(7):609-617. - PMID 34297496 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Annals of internal medicine - 174(2021), 12 vom: 17. Dez., Seite JC136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dunn, Andrew S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abelacimab |
|---|
| Anmerkungen: |
Date Completed 07.02.2022 Date Revised 07.02.2022 published: Print-Electronic CommentOn: N Engl J Med. 2021 Aug 12;385(7):609-617. - PMID 34297496 Citation Status MEDLINE |
|---|
| doi: |
10.7326/ACPJ202112210-136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334077524 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334077524 | ||
| 003 | DE-627 | ||
| 005 | 20231225222946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7326/ACPJ202112210-136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334077524 | ||
| 035 | |a (NLM)34871049 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dunn, Andrew S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-TKA abelacimab reduced VTE at 8 to 12 d compared with enoxaparin |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2022 | ||
| 500 | |a Date Revised 07.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: N Engl J Med. 2021 Aug 12;385(7):609-617. - PMID 34297496 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SOURCE CITATION: Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609-17. 34297496 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Enoxaparin |2 NLM | |
| 650 | 7 | |a abelacimab |2 NLM | |
| 650 | 7 | |a KX1N4TV7UY |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of internal medicine |d 1945 |g 174(2021), 12 vom: 17. Dez., Seite JC136 |w (DE-627)NLM000012777 |x 1539-3704 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2021 |g number:12 |g day:17 |g month:12 |g pages:JC136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7326/ACPJ202112210-136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2021 |e 12 |b 17 |c 12 |h JC136 | ||